Adaptimmune Therapeutics PLC
NASDAQ:ADAP
Adaptimmune Therapeutics PLC
NASDAQ:ADAP
Price:
1.04 USD
-0.95%
Market Closed
Updated:
May 29, 2024
Adaptimmune Therapeutics PLC
Retained Earnings
|
Adaptimmune Therapeutics PLC
Retained Earnings Peer Comparison
Comparables:
CNTA
AUTL
BCYC
IMCR
GNS
Competitive Retained Earnings Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Retained Earnings | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Adaptimmune Therapeutics PLC
NASDAQ:ADAP
|
Retained Earnings
-$1.1B
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
N/A
|
|
|
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
Retained Earnings
-$752.9m
|
CAGR 3-Years
-222%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Autolus Therapeutics PLC
NASDAQ:AUTL
|
Retained Earnings
-$878.6m
|
CAGR 3-Years
-32%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Retained Earnings
-$538.3m
|
CAGR 3-Years
-47%
|
CAGR 5-Years
-48%
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Retained Earnings
-£744.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-35%
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Retained Earnings
£364.1m
|
CAGR 3-Years
5%
|
CAGR 5-Years
6%
|
CAGR 10-Years
8%
|
See Also
What is Adaptimmune Therapeutics PLC's Retained Earnings?
Retained Earnings
-1.1B
USD
-1.1B
USD
Based on the financial report for Mar 31, 2024, Adaptimmune Therapeutics PLC's Retained Earnings amounts to -1.1B USD.
What is Adaptimmune Therapeutics PLC's Retained Earnings growth rate?
Retained Earnings CAGR 5Y
-25%
-25%
Over the last year, the Retained Earnings growth was -18%. The average annual Retained Earnings growth rates for Adaptimmune Therapeutics PLC have been -20% over the past three years , -25% over the past five years .
You don't have any saved screeners yet
